First-Time Generics Of Sanofi-Aventis’ Arava Enter Market
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA appears to have denied Sanofi’s March citizen petition requesting refusal to approve ANDAs without certain bioequivalence studies.